Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

PURPOSE: To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: A total of 43 patients with BRAF V600–mutant mCRC were treated with dabrafenib (150 mg twice...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Corcoran, Ryan B., Atreya, Chloe E., Falchook, Gerald S., Kwak, Eunice L., Ryan, David P., Bendell, Johanna C., Hamid, Omid, Messersmith, Wells A., Daud, Adil, Kurzrock, Razelle, Pierobon, Mariaelena, Sun, Peng, Cunningham, Elizabeth, Little, Shonda, Orford, Keith, Motwani, Monica, Bai, Yuchen, Patel, Kiran, Venook, Alan P., Kopetz, Scott
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2015
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4669588/
https://ncbi.nlm.nih.gov/pubmed/26392102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.63.2471
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg